UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC 20549


                                  FORM 10-QSB



[X]   Quarterly Report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

      For the quarterly period ended  February 28, 2006
                                      -----------------

[ ]   Transition Report pursuant to 13 or 15(d) of the Securities Exchange
      Act of 1934

      For the transition period                  to
                               ------------------   --------------------

      Commission File Number    333-107179
                            -----------------


                             XPENTION GENETICS, INC.
    ------------------------------------------------------------------------
       (Exact name of small Business Issuer as specified in its charter)


                               BAYVIEW CORPORATION
    ------------------------------------------------------------------------
     (Former name, former address and former fiscal year, if changed since
                                 last report)



          Nevada                                         98-0380519
---------------------------------             --------------------------------
(State or other jurisdiction of              (IRS Employer Identification No.)
 incorporation or organization)

10965 Elizabeth Drive
Conifer, CO                                               80433
----------------------------------------      --------------------------------
(Address of principal executive offices)           (Postal or Zip Code)


Issuer's telephone number, including area code:        (303) 908-4900
                                                ------------------------------

<PAGE>

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Securities  Exchange  Act of 1934  during the  preceding  12
months (or for such  shorter  period  that the issuer was  required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days [X] Yes [ ] No

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [X] No [_]

State the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date:  57,625,833 shares of $0.001 par value
common stock outstanding as of April 24, 2006.

Transitional Small Business Disclosure Format        Yes [_]   No [X]


<PAGE>

                          PART I FINANCIAL INFORMATION

Item 1.  Financial Statements




<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                                    Consolidated Balance Sheet
                                        February 28, 2006
                                           (Unaudited)

ASSETS

<S>                                                                         <C>
Current assets
Cash and cash equivalents                                                   $            27,743
                                                                            ====================


LIABILITIES

Current liabilities
Accounts payable                                                            $             5,011
Accrued expenses                                                                        129,901
Note payable                                                                            100,000
                                                                            --------------------
    Total current liabilities                                                           234,912
                                                                            --------------------


STOCKHOLDERS' (DEFICIT)

Preferred stock, $0.001 par value, 10,000,000 shares authorized,
   none issued or outstanding                                                                 -
Common stock, $0.001 par value, 100,000,000 shares authorized,
     57,625,833 shares issued and outstanding                                            57,626
Additional paid-in capital                                                              711,474
Deferred stock compensation                                                             (92,250)
(Deficit) accumulated during the development stage                                     (884,019)
                                                                                 ---------------
                                                                                       (207,169)

                                                                            --------------------

                                                                            $            27,743
                                                                            ====================



         The accompanying footnotes are an integral part of these financial statements.


                                              F-1
</TABLE>

<PAGE>

<TABLE>
<CAPTION>


   XPENTION GENETICS, INC.
                                          (A Development Stage Company)
                                      CONSOLIDATED STATEMENTS OF OPERATIONS
                           THREE MONTHS ENDED FEBRUARY 28, 2006 AND 2005, NINE MONTHS
                      ENDED FEBRUARY 28, 2006, (INCEPTION) OCTOBER 13, 2004 TO FEBRUARY 28,
                           2005, AND (INCEPTION) OCTOBER 13, 2004 TO FEBRUARY 28, 2006
                                                   (Unaudited)



                                                                      Nine Months Ended    (INCEPTION)           (INCEPTION)
                                      Three Months Ended February 28  February 28,       OCTOBER 13, 2004       OCTOBER 13, 2004
                                            2006           2005          2006           TO FEBRUARY 28, 2005  TO FEBRUARY 28, 2006
                                         ------------   -----------   -------------     --------------------  --------------------
<S>                                      <C>            <C>           <C>               <C>                   <C>
Revenues                                 $          -   $        -     $         -       $          -           $         -
                                         ------------   -----------   -------------     ----------------      ----------------

Expenses
 Research and devevelopment                  149,306             -         330,731                  -               330,731
 General and administrative
       non cash stock compensation            92,250             -         276,750                  -               276,750
 General and administrative                   30,611        34,112         116,038             48,390               269,637
                                         ------------   -----------   -------------     ----------------      ----------------
                                             272,167        34,112         723,519             48,390               877,118
                                         ------------   -----------   -------------     ----------------      ----------------

Operating (loss)                            (272,167)      (34,112)       (723,519)           (48,390)             (877,118)
                                         ------------   -----------   -------------     ----------------      ----------------

Other income (expense)
Interest expense                              (1,250)       (1,139)         (3,750)            (1,386)               (6,901)
                                         ------------   -----------   -------------     ----------------      ----------------

Net (loss)                                $ (273,417)    $ (35,251)    $  (727,269)    $      (49,776)       $     (884,019)
                                         ------------   -----------   -------------     ----------------      ----------------

Basic and diluted:
  (Loss) per share                        $    (0.00)   $    (0.00)   $      (0.01)     $         (0.00)      $         (0.02)
                                         ============   ===========   =============     ================      ==================

  Weighted average shares outstanding      57,625,833     56,843,000     57,561,364          56,843,000            57,232,659
                                         ============   ===========   =============     ================      ==================

                 The accompanying footnotes are an integral part of these financial statements.

</TABLE>

                                      F-2

<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                              CONSOLIDATED STATEMENTS OF CASH FLOWS
                   THREE MONTHS ENDED FEBRUARY 28, 2006 AND 2005, NINE MONTHS
        ENDED FEBRUARY 28, 2006, (INCEPTION) OCTOBER 13, 2004 TO FEBRUARY 28, 2005, AND
                        (INCEPTION) OCTOBER 13, 2004 TO FEBRUARY 28, 2006
                                           (Unaudited)




                                                         Nine Months Ended           (INCEPTION)               (INCEPTION)
                                                           February 28,           OCTOBER 13, 2004          OCTOBER 13, 2004
                                                              2006              TO FEBRUARY 28, 2005      TO FEBRUARY 28, 2006
                                                      ---------------------------------------------------------------------
<S>                                                   <C>                <C>                     <C>
Cash Flows From Operating Activities
Net (loss)                                            $      (727,269)   $             (49,776)  $                (884,019)
Adjustments to reconcile net (loss) to
net cash (used in) operating activities
      Stock compensation expense                              276,750                        -                     276,750
      Prepaid expenses                                              -                  (15,000)                          -
      Accounts payable and accrued expenses                       62,840                   34,248                     134,912
                                                    -----------------------------------------------------------------------
Cash flows (used in) operating activities                    (387,679)                 (30,528)                   (472,357)
                                                    -----------------------------------------------------------------------

Cash Flows From Investing Activities
Cash flows provided by (used in) investing
activities                                                          -                        -                           -
                                                    -----------------------------------------------------------------------

Cash Flows From Financing Activities
   Proceeds from note payable                                       -                  100,000                     100,000
Proceeds from issuance of common stock                        400,000                      100                     400,100
                                                    -----------------------------------------------------------------------
Cash flows provided by financing activities                   400,000                  100,100                     500,100
                                                    -----------------------------------------------------------------------

Increase in cash                                               12,321                   69,572                      27,743

Cash, beginning of period                                      15,422                        -                           -
                                                    -----------------------------------------------------------------------

Cash, end of period                                   $        27,743    $              69,572   $                  27,743
                                                    =======================================================================


Supplemental cash flow information
  Income taxes paid                                   $             -    $                   -   $                       -
                                                    =======================================================================
  Interest expense paid                               $         5,000    $                   -   $                   5,000
                                                    =======================================================================


         The accompanying footnotes are an integral part of these financial statements.
</TABLE>


                                      F-3

<PAGE>



                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                February 28, 2006
                                   (Unaudited)


NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Financial Statements

The accompanying unaudited financial statements of Xpention Genetics,  Inc. have
been prepared in accordance with generally  accepted  accounting  principles for
interim financial  information and with the instructions to Form 10-QSB and Rule
10-01 of  Regulation  S-X.  The  financial  statements  reflect all  adjustments
consisting of normal recurring adjustments, which, in the opinion of management,
are  necessary  for a fair  presentation  of the results for the periods  shown.
Accordingly,  they do not include all of the information and footnotes  required
by generally accepted accounting principles for complete financial statements.

These  financial  statements  should  be read in  conjunction  with the  audited
financial  statements and footnotes  included  thereto for the fiscal year ended
May 31, 2005, for Xpention  Genetics,  Inc. on Form 10KSB, as amended,  as filed
with the Securities and Exchange Commission.

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
that effect the reported  amounts of revenues and expenses  during the reporting
period. Actual results could differ from those estimates.

Organization

Xpention Genetics,  Inc. (the Company) was incorporated in the State of Colorado
on October 13, 2004, and has been in the development  stage since its inception.
In March 2005, the Company  entered the  biotechnology  industry to develop both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human cancers.  In March 2005 the Company changed its name to Xpention Genetics,
Inc. The Company has been in the  development  stage since its formation and has
not yet  realized  any  revenues  from its planned  operations.  The Company has
chosen May 31 as its fiscal year-end.

During March 2005 Bayview  issued  14,300,000  shares of its common stock to the
shareholders  of the  Xpention,  Inc.  in  exchange  for all of the  issued  and
outstanding  common  shares of  Xpention  pursuant to an  Agreement  and Plan of
Reorganization.  In addition,  Concurrent  with the exchange of shares,  Bayview
changed its name to Xpention Genetics, Inc.

                                      F-5

<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                February 28, 2006
                                   (Unaudited)

This   acquisition  of  Xpention,   the  accounting   acquirer,   by  Bayview  a
non-operating  entity,  is considered in substance a capital  transaction by the
issuance of  14,300,000  shares of common stock by Bayview for all of the issued
and  outstanding  common  shares of  Xpention,  and will be  accounted  for as a
reverse  acquisition,  and no  goodwill  or  other  intangible  assets  will  be
recorded.  On this basis, the historical financial statements as of and prior to
the acquisition date will represent the operations of Xpention.

Net (Loss) Per Common Share

The Company  follows SFAS 128,  "Earnings Per Share".  Basic earnings (loss) per
common share  calculations  are  determined by dividing net income (loss) by the
weighted average number of shares of common stock  outstanding  during the year.
Diluted earnings (loss) per common share calculations are determined by dividing
net income (loss) by the weighted  average  number of common shares and dilutive
common  share  equivalents  outstanding.   During  the  periods  when  they  are
anti-dilutive,  common  stock  equivalents,  if any, are not  considered  in the
computation.


NOTE 2. COMMITMENTS

On May 31, 2005, the Company  entered into a Research  Agreement with AMC Cancer
Research  Center  for  research  activities  for  the  development  of  the  p65
immunological  test for canines.  The estimated cost for the project was $58,946
the  agreement  expired  on  January  30,  2006,  and no  payments  were made or
required.

On May 28, 2005, the Company  entered into a Research  Contract with  Genethera,
Inc. for research  activities for the development of the p65 molecular assay for
canines.  The contract became  effective on May 28, 2005, and expires on May 30,
2006,  and requires  payments to  Genethera  of $20,000 per month.  Payments are
current through February 28, 2006.

On May 28, 2005,  the Company  entered into a Research  Agreement with Genethera
Inc. for research  activities for the development of the p65 molecular assay for
humans. The agreement became effective on July 28, 2005, and expires on July 28,
2006, and requires payments to Genethera Inc. of $10,000 per month. Payments are
current through February 28, 2006.

On February 17, 2005,  the  Company's  wholly-owned  subsidiary  Xpention,  Inc.
entered into a License and Technology Licensing Agreement with the University of
Texas  M.D.  Anderson  Cancer  Center  (UTMDACC)  to  commercialize   technology
developed for cancer  detection in animals and humans.  The Company paid $50,000

                                      F-6

<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                February 28, 2006
                                   (Unaudited)

for the  license  which was  expensed  during the year ended May 31,  2005.  The
Agreement  call for a 5.5% royalty to be paid to UTMDACC on the sale of products
utilizing the licensed technology.  In addition payments of $50,000 each are due
upon the  first  sales to both the  veterinary  market  and  human  market.  The
Agreement expires in February 2020.

On July 21, 2005,  the Company  entered into a Research  Agreement with Colorado
State  University for research  activities in connection with the development of
the p65  immunological  test for canines in which CSU will provide  canine blood
and tissue  specimens for use in clinical  trials.  The agreement  terminates on
July 1, 2006, and requires  payments to CSU totaling  $17,520.  Payments through
February 28, 2006 were $16,425.

On November 2, 2005,  the Company  amended its Research  Agreement with Colorado
state  University.  The  amendment  calls for CSU to  collect  additional  blood
samples for use by the Company in development of a canine cancer  detection test
and extends the  agreement  to November 1, 2006.  The Company  will pay Colorado
State  University an additional  $15,330 for the work performed  pursuant to the
amendment.

On December 1, 2005,  the company  entered  into a Research  Agreement  with The
University of Texas Health  Science  Center at San Antonio  ("UTHSCSA")  whereby
UTHSCSA  agreed  to  perform   research   activities   for   development  of  an
immunological  test for canines.  This agreement replaces the Research Agreement
the Company  entered into with AMC Cancer  Research Center in May 2005 which has
been  relinquished by AMC. The agreement with UTHSCSA will permit the Company to
continue its  collaboration  with Dr.  Margaret  Hanausek who accepted a faculty
position at UTHSCSA.  The Company will pay $64,306 to UTHSCSA for work performed
pursuant to the Agreement. Payments through February 28, 2006 were $59,306.


NOTE 3. NOTE PAYABLE

The Company's wholly-owned subsidiary entered into a loan agreement for $100,000
on November 12, 2004.  Interest  accrues at a rate of 5.0% per annum. The note's
original maturity date was November 12, 2005, however, on that date, the parties
agreed to extend the note to March 1, 2006.

NOTE 4. COMMON STOCK

On June 28,  2005,  the Company  entered into a  Consulting  Agreement  with Dr.
Thomas Slaga for general scientific research assistance. The agreement continues
until at least  May 31,  2006.  The  Company  granted  Slaga  450,000  shares of
restricted  common  stock as  compensation  for such  services.  The shares were

                                      F-7

<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                February 28, 2006
                                   (Unaudited)

valued  at their  fair  market  value on the date it was  agreed  they  would be
issued.  During the period  $102,665 has been charged to  operations as research
and  development  and $92,250  has bee  recorded  as  deferred  compensation  at
November 30, 2005.

On June 15, 2005,  the Company  entered  into a  Subscription  Agreement  with a
private  investor for the sale of 333,333 shares of restricted  common stock for
cash at a price of $1.20 per share.










                                      F-8


<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation

FORWARD LOOKING STATEMENTS

This quarterly report contains forward-looking statements that involve risks and
uncertainties.  We use words such as anticipate,  believe, plan, expect, future,
intend and similar expressions to identify such forward-looking  statements. You
should not place too much  reliance  on these  forward-looking  statements.  Our
actual results are likely to differ  materially from those  anticipated in these
forward-looking  statements  for many  reasons,  including the risks faced by us
described in this Risk Factors section and elsewhere in this annual report.

Plan of Operation

The Company, through its wholly-owned subsidiary,  holds the exclusive worldwide
license for  patented  technology  for the  detection of cancer based on a tumor
marker known as p65 which has been  demonstrated  to have elevated levels in the
blood of canine and human  cancer  conditions.  p65 is  believed to be a protein
required in the early  development  of numerous  cancers and appears  from early
research  to provide a strong  indication  of tumor  growth in both  canines and
humans.  It also appears to have a direct  correlation to tumor size/mass making
it a promising  marker for both early  detection of malignant tumor formation as
well as a useful tool for  monitoring  therapy  and  remission.  Initially,  the
Company plans to develop an immunological  test as well as a molecular assay for
detection  of  cancer  in  canines.  The  Company  also  plans to  develop  both
immunological  and  molecular  tests for  detection of human  cancers as well as
therapeutic treatments and vaccines.

During the interim  period ended  February 28, 2006,  the Company  continued its
research  activities  for the  development  of an  immunological  canine  cancer
detection  test as well as a  molecular  assay for  detection  of cancer in both
canines and humans,  all of which are being conducted by third parties on behalf
of the company.  The Company  also  continues  to evaluate  various  options for
commercialization  of its  products;  however,  it is not  anticipated  that the
Company will generate any revenues from commercialization of its products during
FY 2006.

Results of Operations for the Period Ended February 28, 2006

The  Company  did not earn any  revenues  during the  three-month  period  ended
February 28, 2006.  For the  three-month  period  ended  February 28, 2006,  the
Company incurred expenses totaling $272,167  including  research and development
expenses of $149,306,  administrative expenses of $30,611 and stock compensation
(non-cash) of $92,250 plus interest  expense of $1,250 for a net loss during the
period of $273,417.  The Company  issued  333,333  shares of stock at a price of
$1.20 per share in June 2005 generating  $400,000 in cash, the proceeds of which
were used to cover research and development  expenses as well as  administrative
expenses  of the Company  during the period.  For the  nine-month  period  ended
February 28, 2006, the Company incurred  expenses  totaling  $723,519  including
research  and  development  expenses  of  $330,731,  administrative  expenses of
$116,038 and stock compensation  (non-cash) of $276,750 plus interest expense of
$3,750 for a net loss  during  the  period of  $727,269.  Since  inception,  the
Company has not  generated  any  revenues  and has  incurred  expenses  totaling
$877,118  plus  interest  expense of $ 6,901 for a net loss since  inception  of
$884,019. Need to include comparatives to prior period.

<PAGE>

At February 28, 2006, the Company had $27,743 in cash on hand,  accounts payable
and accrued expenses totaling $134,912 and note payable of $100,000.


Item 3.  Controls and Procedures

Evalution of Disclosure Controls

Management evaluated the effectiveness of the disclosure controls and procedures
as of the end at February 28, 2006.  This  evaluation was conducted by the chief
executive officer and principal accounting officer.

Disclosure  controls  are  controls  and other  procedures  that are designed to
ensure that  information  that is  required  to  disclose  in the reports  filed
pursuant  to  the  Securities  Exchange  Act of  1934  is  recorded,  processed,
summarized and reported.

Limitations on the Effective of Controls

Management does not expect that the disclosure controls or the internal controls
over financial  reporting will prevent all error and fraud. A control system, no
matter how well  conceived and  operated,  can provide only  reasonable,  but no
absolute,  assurance that the  objectives of a control system are met.  Further,
any control  system  reflects  limitations  on resources,  and the benefits of a
control system must be considered  relative to its costs. These limitations also
include the realities that judgments in  decision-making  can be faulty and that
breakdowns can occur because of simple error or mistake. Additionally,  controls
can be circumvented by the individual acts of some persons,  by collusion of two
or more people or by  management  override  of a control.  A design of a control
system is also based upon certain assumptions about potential future conditions;
over time,  controls may become inadequate because of changes in conditions,  or
the degree of  compliance  with the  policies  or  procedures  may  deteriorate.
Because  of  the  inherent  limitations  in  a  cost-effective  control  system,
misstatements due to error or fraud may occur and may not be detected.

Conclusions

Based upon his  evaluation  of the  controls,  the chief  executive  officer and
principal  accounting  officer has concluded  that,  subject to the  limitations
noted  above,  the  disclosure  controls  are  effective  providing   reasonable
assurance  that  material  information  relating to the Company is made known to
management  on a timely  basis  during the  period  when the  reports  are being
prepared.  There were no changes in the internal  controls that occurred  during
the  quarter  covered  by this  report  that have  materially  affected,  or are
reasonably likely to materially affect the internal controls.

<PAGE>

                           PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is not a party to any pending legal proceeding.  Current  management
is not aware of any threatened litigation, claims or assessments.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The Company did not issue any unregistered  securities  during the quarter ended
February 28, 2006.


Item 3. Defaults Upon Senior Securities

         None.


Item 4. Submission of Matters to a Vote of Security Holders

         None.


Item 5. Other Information

         None.


Item 6. Exhibits and Reports on Form 8-K

        A.  Exhibits

            31      Certification pursuant to 18 U.S.C. Section 1350, as adopted
                    pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

            32      Certification pursuant to 18 U.S.C. Section 1350, as adopted
                    pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        B.  Reports on Form 8-K

            8-K filed on March 9, 2006

            8-K filed on March 16, 2006

<PAGE>

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

Dated:  April 24, 2006

                                        Xpention Genetics, Inc.

                                        /s/ David Kittrell
                                        ------------------------------
                                        David Kittrell, President